HydroPeptide Lash Longer Fuller Lusher is rapidly gaining popularity in the US as the new lash product due to its drug-free formulation and impressive results. HydroPeptide Lash’s popularity is partly due to the fact that the product does not contain “glaucoma type meds” like Latisse®, Peter Thomas Roth Lashes To Die for, Lilash or MD Lash Factor. The FDA is taking action against the other products because the “use of Age Intervention Eyelash may cause other adverse effects in certain people due to the bimatoprost, including macular edema (swelling of the retina) and uveitis (inflammation in the eye), which may lead to decreased vision.”

Galderma, the leading pharmaceutical company in dermatology, and Ipsen, an international innovation-driven specialty pharmaceutical group, announced that Azzalure® (botulinum toxin type A manufactured by Ipsen), has received a marketing authorization in Spain from the Spanish Medicines and Healthcare Products Agency (AEMPS). Azzalure is a local muscle relaxant specifically developed for aesthetic use and has been approved for the temporary improvement in the appearance of moderate to severe glabellar lines seen at the frown (vertical lines between the eyebrows), in adult men and women aged up to 65 years, when the severity of these lines has an important psychological impact on the patient.

The Harley Medical Group has seen a 22% year on year rise in people grooming themselves in the pre-summer season. Laser hair removal has proven to be the most popular of all The Harley Medical Group non-surgical procedures across its 26 UK clinics. Laser hair removal usually requires six to eight courses of laser treatments. The most common areas in women are the face, neck, bikini line, underarms and legs. The most common areas in men are the face, neck, back and chest. The treatment can even be performed in a lunch break for busy businessmen.

The FDA has approved additional strengths of Medicis’ SOLODYN(R) (minocycline HCl, USP) Extended Release Tablets for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 12 years and more. The drug will now be available in 65mg and 115mg dosages also. “These additional strengths will complement the current SOLODYN lineup to offer physicians more precise weight-based dosing options, and make SOLODYN the first and only extended release minocycline with five FDA-approved dosing strengths. We believe physicians and patients will appreciate the value of this greater dosing precision,” Jonah Shacknai, Chairman and Chief Executive Officer of Medicis said.